Henlius, Hansoh, and Jiangzhong Report Strong 2024 Financial Results Amid Strategic R&D Investments

Mar 25, 2025 18:48 CST Updated 18:48

Henlius

Innovative Biopharmaceutical Company

Hansoh Pharma

Pharmaceutical Research, Production, and Sales

JZJT

Traditional Chinese Medicine Manufacturer

Shanghai Henlius Biotech, Inc. Revenue Exceeds 5.7 Billion Yuan in 2024

On March 24, Shanghai Henlius Biotech, Inc. released its 2024 annual performance, achieving operating revenue of approximately RMB 5.7244 billion during the performance period, representing an increase of about 6.1% compared to the same period last year. Net profit reached RMB 820.5 million, a year-on-year increase of 50.3%, with a net profit margin of 14.3%, up by 41.6% year-on-year. The continuous expansion of commercial sales of core products has become a significant driver of profitability, with total product sales revenue reaching approximately RMB 4.9335 billion, a year-on-year increase of 8.3%. Additionally, the company's total R&D investment for the year reached RMB 1.8405 billion, a year-on-year increase of 28.4%.

In 2024, Shanghai Henlius Biotech, Inc. focuses on unmet clinical needs and continues to advance in the innovative field centered around antibody technology, committing to accelerate more potential "First-in-Class" and "Best-in-Class" molecules into the clinical development stage. The company continuously builds and optimizes its Antibody-Drug Conjugate (ADC) technology platform and T Cell Engager (TCE) technology platform, fully utilizing cutting-edge technologies represented by AI to provide robust support for innovative R&D. In terms of clinical development, the company actively promotes the clinical development of innovative products such as HANSIZHUANG®, HLX22 (anti-HER2 monoclonal antibody), and HLX43 (PD-L1 ADC).

Hansoh Pharma's 2024 Profit Exceeds 4.37 Billion Yuan

On March 21, Hansoh Pharma announced its full-year financial results for 2024. In 2024, the company's revenue reached RMB 12.261 billion, representing a year-on-year increase of 21.3%. Revenue from innovative drugs and collaborative products amounted to RMB 9.477 billion, accounting for 77.3% of total revenue. Net profit attributable to shareholders of the listed company was RMB 4.372 billion, marking a year-on-year increase of 33.4%. The company invested RMB 2.702 billion in R&D, reflecting a year-on-year growth of 28.8%, which accounted for 22.0% of total revenue.

Currently, Hansoh Pharma has commercialized eight innovative drugs, with one at the NDA stage. Among these, three are in-licensed products, including the commercial rights in China for Selinexor from Antengene, CD19 monoclonal antibody from Viela, and Ibrexafungerp from Scynexis. In terms of self-developed products, a representative drug from Hansoh Pharma is Aumolertinib, the first domestically produced third-generation EGFR inhibitor in China. Other notable drugs include Metronidazole Miconazole, Losenatide, Fluoromatinib, Aimitinib Fumarate, and Pemostim.

Jiangzhong Pharmaceutical Co.,Ltd. 2024 Revenue of 4.435 Billion Yuan

3Month20Date, JZJT Release2024Annual Report. CompanyOperating Revenue44.35Hundred MillionYuan, Adjusted for the same period last year45.53Hundred MillionYuan, year-on-yearReduce2.59%；Net Profit Attributable to Shareholders7.88Hundred MillionYuan, Adjusted same period last year7.08Hundred MillionYuan, year-on-year growth9.67%；Non-recurring Net Profit7.49Hundred MillionYuan, Adjusted same period last year7.03Hundred MillionYuan, year-on-year growth6.43%；Operating Cash Flow7.86Hundred MillionYuan, the same period last year10.39Hundred MillionYuan`, year-on-year`Reduce24.36%。

Revenue from each segment is as follows: Over-the-counter drug revenue was 3.266 billion yuan, a year-on-year increase of 7.07%, with a gross margin of 72.74%, up 1.04 percentage points year-on-year. Health consumer products and other revenue was 345 million yuan, a year-on-year decrease of 47.30%, with a gross margin of 37.72%, up 0.62 percentage points year-on-year. Prescription drug revenue was 793 million yuan, a year-on-year decrease of 3.50%, with a gross margin of 39.30%, down 17.54 percentage points year-on-year. Other business revenue was 31 million yuan.

Editor: Li Yongshi

Layout Editor: Yu Yuanze

Reviewed by: Ma Fei, Zhang Song